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Only anti-CD133 antibodies
recognizing the CD133/1 or the
CD133/2 epitopes can identify
human renal progenitors
To the Editor: Ivanova et al.1 describe the expression of
CD24 and CD133 in developing human kidneys. Their study is
based on our previous reports, showing the existence of
a CD24þCD133þ renal progenitor population in human
kidney.2,3 In agreement with our results, they show that CD24 is
a reliable marker to detect and purify human renal progenitors,
whereas they are unable to obtain a further enrichment of
human renal progenitors using CD133 as an additional marker,
as we previously reported.2,3 However, Ivanova et al. used anti-
CD133 polyclonal antibodies, which stained diffusely differ-
entiated epithelial structures in embryonic, as well as adult
kidneys.1 By contrast, we used anti-CD133 monoclonal
antibodies recognizing CD133/1 (clone AC133) or CD133/2
(clone 293C3) epitopes, which selectively recognized renal
progenitors.2,3 It is common knowledge in the stem-cell ﬁeld
that only anti-CD133/1 or anti-CD133/2 antibodies can be used
to detect and purify stem cells in several human tissues, whereas
other anti-CD133 antibodies show expression in differentiated
cells.4 Recent studies have clariﬁed this apparent discrepancy.5
Indeed, different tertiary structures of the CD133 molecule
justify the diverse accessibility of the CD133/1 or CD133/2
epitopes in undifferentiated versus differentiated cells.5 Differ-
ential recognition of CD133 mRNA variants has also been
suggested.4 Consistently, double-label immunoﬂuorescence per-
formed with anti-CD133 antibodies used by Ivanova et al. and
anti-CD133/1 or anti-CD133/2 antibodies, conﬁrmed that only
the latter recognized human renal progenitors (Figure 1). Thus,
we recommend the usage anti-CD133/1 or CD133/2 antibodies
to detect or purify human renal progenitors.
1. Ivanova L, Hiatt MJ, Yoder MC et al. Ontogeny of CD24 in the human
kidney. Kidney Int 2010; 77: 1123–1131.
2. Sagrinati C, Netti GS, Mazzinghi B et al. Isolation and characterization of
multipotent progenitor cells from the Bowman’s capsule of adult human
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Figure 1 |Only antibodies recognizing the CD133/1 or CD133/2
epitopes can identify human renal progenitors. (a, b)
Double-label immunofluorescence performed with the anti-CD133
polyclonal antibody used by Ivanova et al. (pCD133, red) and
the anti-CD133/2 monoclonal antibody (green) in embryonic
human kidneys. The anti-CD133 antibody used by Ivanova et al.
poorly stains primary vesicles, comma-shaped bodies and S-
shaped bodies, while it extensively stains differentiated tubular
cells as well as the differentiating ureteric bud (red). By contrast,
the anti-CD133/2 antibody (green) selectively stains condensed
mesenchyme-derived primordial structures, primary vesicles,
comma-shaped bodies, S-shaped bodies and, in maturing
glomeruli, the urinary pole of the Bowman’s capsule (arrows).
In (b), asterisk indicates a maturing glomerulus. Merged areas
appear in yellow. Topro-3 counterstains nuclei (blue). Bar 100mm.
(b0) Split image of the maturing glomerulus identified by the
asterisk in (b). The arrow indicates the urinary pole of the
Bowman’s capsule. Bar 50mm (c) Double label immuno-
fluorescence performed with the anti-CD133 polyclonal antibody
used by Ivanova et al. (pCD133, red) and the anti-CD133/1
monoclonal antibody (green) in embryonic human kidneys.
Only CD133/1 antibody selectively stains human progenitors of
the Bowman’s capsule (arrow). Merged areas appear in yellow.
Topro-3 counterstains nuclei (blue). Bar 100mm.
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The Authors Reply: We thank Dr Angelotti et al.1 for their
comments regarding our paper deﬁning the ontogeny of CD24
in the human kidney,2 and for their suggestions for the use of
anti-CD133 monoclonal antibodies to the CD133/1 and
CD133/2 epitopes for the selection and puriﬁcation of renal
progenitor cells. We would like to emphasize that the purpose
of our report was to deﬁne, using high quality immunohisto-
chemical analyses of human fetal kidneys, the precise spatial
and temporal localization of CD24, so as to suggest potential
roles of this cell-surface antigen in normal and abnormal
human kidney development.
We of course defer to views of Dr Angelotti et al. regarding
the best technique of isolation of kidney progenitor cells, but
we would disagree with their interpretation of our results on
CD133 expression. In fact, although CD133 expression using
our polyclonal antibody was less restricted than theirs, we did
in fact show co-localization of CD133 and CD24 in early
developing nephron epithelial structures, which, given post-
natal CD133 (or prominin) expression, not surprisingly
express this antigen.
Finally, although the CD133/1 and CD133/2 epitopes may
be more speciﬁc to renal progenitors, we suspect that some of
the differences seen in our work and theirs, may have more to
do with immunohistochemistry technique, sample collection,
and tissue ﬁxation, on the basis of the details of their included
photomicrographs.
1. Angelotti ML, Lazzeri E, Lasagni L et al. Only anti-CD133 antibodies
recognizing the CD133/1 or the CD133/2 epitopes can identify human
renal progenitors. Kidney Int 2010; 78: 620–621.
2. Ivanova L, Hiatt MJ, Yoder MC et al. Ontogeny of CD24 in the human
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Paraproteinemia-associated
pseudohypercreatininemia across
different analytical methodologies
To the Editor: The case reported by Rudofsky et al.1
illustrated that clinicians and laboratorians need to be
cautious of potential analytical interference secondary to
paraproteinemia. Recently, we encountered an 81-year-old
man with history of IgM k myeloma and elevated creatinine
concentration of 6.5mg/dl (normal: 0.7–1.2mg/dl), deter-
mined using the modiﬁed Jaffe´ method by Roche (Mannheim,
Germany) DP Modular Analytics analyzer. Considering
patient’s poor premorbid status, conservative and supportive
management of renal failure was decided.
The discrepant urea to creatinine ratio and all along normal
potassium concentrations were noticed by the chemical
pathologist. Distorted reaction curve was noted upon data
retrieval. Serial dilution of patient specimen with quality control
material showed the creatinine concentration was only 2.1mg/
dl. Creatinine level was measured as 1.7mg/dl by enzymatic
method with J&J Vitros (Raritan, NJ, USA) dry chemistry ana-
lyzer. Serum cystatin C was 1.17mg/l (normal: 0.50–1.00mg/l).
Physicians were contacted and ﬁndings explained.
Paraproteins interfering with Jaffe´ method for creatinine
determination have been reported.2 Analyses of numerous
clinically important analytes and electrolytes can be interfered
by paraproteins in an extremely unpredictable manner,
affecting different methodologies of automated assays. There
is poor correlation between the subtype and level of
paraproteins and the likelihood of in vitro interference.3
Enhanced clinical alertness helps picking up false results and
prevents patient damages, including anxiety and medication
underdosing. From the laboratory’s perspective, proper
procedures in handling specimens with paraproteins should
be in place and appropriately documented. Platforms with
alternative methodologies should be readily accessible in
processing doubtful cases. Interpretation and authorization of
abnormal results by chemical pathologists can further
minimize reporting misleading results directly from auto-
mated analyzers. Finally, the importance of effective commu-
nications between physicians and chemical pathologists
cannot be overemphasized.
1. Rudofsky G, Villalobos M, Waldherr R et al. The case: renal failure in a male
with Waldenstro¨m’s macroglobulinemia. Kidney Int 2010; 77: 371–372.
2. Datta P, Graham GA, Schoen I. Interference by IgG paraproteins in the Jaffe
method for creatinine determination. Am J Clin Pathol 1986; 85: 463–468.
3. Roy V. Artifactual laboratory abnormalities in patients with
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The Authors Reply: Short time after our report of a patient
with pseudohypercreatininemia due to Waldenstro¨m’s macro-
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